Helius Medical Technologies, Inc. Announces FDA Has Granted the PoNS Device Breakthrough Device Designation for the Treatment of Gait Deficits Due to Symptoms of Multiple Sclerosis

Stock Information for Helius Medical Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Helius Medical Technologies Inc.

Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy(TM)
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
Helius Booth and Special Event at APTA Combined Sections Meeting Will Highlight Physical Therapists' Ability to Customize PoNS Therapy® to Improve Gait in People with MS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.